EXTENDED REPORT

Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors

Marzena Ciechomska, Christiaan A Huigens, Thomas Hügle, Tess Stanley, Andreas Gessner, Bridget Griffiths, Timothy R D J Radstake, Sophie Hambleton, Steven O’Reilly, Jacob M van Laar

ABSTRACT

Objectives To investigate whether monocytes contribute to matrix deposition in systemic sclerosis (SSc) by production of tissue-inhibitor of metalloproteinase-1 (TIMP-1).

Methods Matrix metalloproteinase-1 (MMP-1) and TIMP-1 expression and secretion were measured by qRT-PCR and ELISA in circulating monocytes from patients with SSc, patients with rheumatoid arthritis (RA) and healthy controls (HC) and in healthy monocytes cultured in the presence of SSc or HC serum samples. Production of TIMP-1 was determined in response to a panel of Toll-like receptor (TLR) agonists and MyD88 inhibitory peptide. The functional effect of conditioned media from SSc and HC serum samples or TLR8-stimulated monocytes was studied in an MMP-1 activity assay.

Results TIMP-1 production by monocytes was upregulated in patients with SSc compared with patients with RA and HC. Incubation of HC monocytes with SSc serum samples resulted in functionally active TIMP-1 production. However, pretreatment with MyD88 inhibitor, but not control peptide, decreased TIMP-1 secretion. TIMP-1 production was significantly stronger when SSc and HC monocytes were stimulated with TLR8 (ssRNA) agonist, but the response was more pronounced in SSc monocytes. TIMP-1 production after TLR stimulation was significantly stronger when SSc monocytes were stimulated with TLR8 (ssRNA) agonist, but the response was more pronounced in SSc monocytes. TIMP-1 production was significantly inhibited in media from serum samples or TLR8-stimulated monocytes indicative of functional TIMP activity.

Conclusions This study demonstrates profibrotic properties of circulating monocytes from patients with SSc and a key role for TLR signalling, particularly TLR8, in TIMP-1 secretion and matrix remodelling.

INTRODUCTION

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterised by vasculopathy and fibrosis of the skin and inner organs. Low-grade inflammation with tissue infiltration by mononuclear cells plays an important role in fibrogenesis. Fibrosis in SSc is characterised by extensive accumulation of extracellular matrix (ECM), including collagen. In addition to increased secretion of ECM components, impaired breakdown of the ECM can also contribute to fibrosis. ECM breakdown is mainly mediated by matrix metalloproteinases (MMPs), a family of endopeptidases capable of degrading all matrix components. Tissue inhibitors of metalloproteinase (TIMPs) selectively inhibit these peptidases, thus inhibiting ECM breakdown. The TIMP family consists of four members; of which, TIMP-1 is a key enzyme as it can inhibit most MMPs. Several studies have reported increased serum concentrations of TIMP-1 and increases in the ratio of TIMP/MMP in both tissue and blood of patients with SSc. Wound healing studies have shown that TIMP-1 expressed by inflammatory cells such as monocytes or macrophages is important in tissue remodelling. Studies have identified circulating monocytes as key inflammatory cells in SSc, but which factor drives TIMP-1 is still undefined.

Toll-like receptors (TLRs) are integral components of the innate immune system that recognise pathogen-encoded TLR ligands, including viral and bacterial fragments. Most TLRs function through the myeloid differentiation protein 88 (MyD88) adapter protein. Homodimerisation of MyD88 is a critical step in the downstream signalling process, which allows the recruitment and activation of the interleukin 1 receptor (IL-1R)-associated kinase (IRAK), consequently leading to the expression of proinflammatory and profibrotic cytokines, chemokines, but also collagen. MyD88-deficient rats and mice are protected from fibrosis, pathological inflammation and cardiac hypertrophy, implying a crucial role for MyD88 in fibrogenesis. TLK-mediated activation can also be induced by recognition of self-reactive nucleic acids that bind to intracellular TLR7, 8 or 9, consequently initiating the breakdown of tolerance and promoting the development of autoimmune disease. It was previously reported that autoantigens can bind to IgG and form immune complexes (ICs) that subsequently induce interferon α (IFNα) production by plasmacytoid dendritic cells (pDCs) in systemic lupus erythematosus (SLE) and Sjögren’s syndrome. However, whether a similar mechanism is at play in SSc is unknown. Here we show that SSc monocytes stimulated with TLR agonists, in particular TLR8 (ssRNA), produce TIMP-1, leading to a shift in the balance between MMP-1 and TIMP-1 and altered
matrix remodelling in vitro. Furthermore, serum samples from patients with SSc are a source of MyD88-dependent TLR agonists driving TIMP-1 production and therefore promoting fibrosis development. Our findings point to a critical role of circulating monocytes in fibrogenesis in SSc.

MATERIALS AND METHODS

Patients and controls

Twenty-three patients with SSc, 29 healthy controls (HC) and 21 patients with active rheumatoid arthritis (RA) were included in the study. All patients with SSc fulfilled the American College of Rheumatology criteria according to LeRoy. Cells from an IRAK4-deficient patient were also used in this study, characterised by impairment of neutrophil CD62L shedding and absent cytokine responses to TLR ligands, typical of patients with autosomal recessive deficiency of IRAK4 or MyD88.22 23

Sample collection and cell purification

Blood was collected in EDTA-coated tubes from HC, patients with SSc or patients with RA during standard outpatient procedures and processed within 4 h of collection. Peripheral blood mononuclear cells were separated from whole blood by Ficoll-Hypaque density gradient centrifugation (Axis-shield). CD14 monocytes were isolated from peripheral blood mononuclear cells, according to the manufacturer’s protocol, with the CD14 MACS beads isolation kit (Miltenyi-Biotec, Bergisch Gladbach, Germany). Purified monocytes were removed from the column and tested for purity by flow cytometry (showing >95% purity for CD14+CD3– cells). Serum samples were collected in ‘serum separation tubes’ (Grainer, Vacuette), aliquoted and frozen at −20°C. Some HC and SSc serum samples were also pretreated for 4 h with 4 units of benzonase (showing >95% purity for CD14+CD3– cells). Serum samples were also pretreated for 4 h with 4 units of benzonase and 10% serum from patients with SSc, patients with RA or HC at 37°C in 5% CO2.

In vitro monocyte cultures

CD14 monocytes from HC or patients with SSc were seeded in 48-well Costar plates at a concentration of 1 × 106 cells/ml and cultured for 4–24 h in 300–600 µl of Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM) (all Sigma) and 10% serum from patients with SSc, patients with RA or HC at 37°C in 5% CO2.

Stimulation and immunohistochemistry of TLR agonists

A human TLR1–9 Agonists Kit was purchased from InvivoGen, resuspended in endotoxin-free water and stored in sterile conditions at −20°C. The set of TLR 1–9 agonists was used at the following concentrations: TLR1/2 (Pam3CSK4) (1 µg/ml), TLR2 (HKLKM) (106 cells/ml), TLR3 (poly-IC) (1 µg/ml), TLR4 (lipopolysaccharide) (1 µg/ml), TLR5 (flagellin) (1 µg/ml), TLR6/2 (FSL-1) (1 µg/ml), TLR7 (imiquimod) (1 µg/ml), TLR8 (ssRNA40) (1 µg/ml), TLR9 (ODN2006 type B) (5 µM). A MyD88 Homodimerisation Inhibitory Peptide Set (Imgenex, IMC-2005–5) was resuspended in phosphate-buffered saline and used at 50 µM, as recommended by the manufacturer. A paraffin-embedded skin section from a patient with SSc was stained with goat anti-human CD14 (Abcam, ab45870) and mouse anti-human TIMP-1 (Abcam, ab1827) primary antibodies overnight at 4°C and with secondary antibodies (Invitrogen, anti-goat-Alexa-Fluor488 and anti-mouse-Alexa-Fluor546, respectively). The skin section was further analysed by confocal microscopy.

Semiquantitative MMP-1 and TIMP-1 gene expression analysis

RNA from freshly isolated monocytes was obtained using the RNA mini kit (Qiagen), according to the manufacturer’s protocol. RNA (200–750 ng) was treated with DNase and reverse transcribed to cDNA with the use of random hexamers and the Moloney murine leukaemia virus reverse transcriptase enzyme (Invitrogen), according to the manufacturer’s protocol. cDNA (20 ng), forward and reverse primer and probe in Taq ready mastermix were used for TIMP-1 expression analyses (see online supplementary table S1). MMP-1 expression was analysed using SYBR Green mix. Samples were analysed in triplicate and normalised to the 18S housekeeping gene using the AB7500 (Applied Biosystems) qRT-PCR machine and programme. Expression levels relative to the average healthy control (arbitrarily set at 1) were calculated using the following equation: \(2^{-\Delta \Delta CT}\) all normalised to 18S housekeeping gene. Primers, probes and Taq ready mastermix were used according to the manufacturer’s protocol (Sigma-Aldrich, St Louis, MO, USA).

TIMP and MPP ELISA

TIMP-1, TIMP-2, MPP-1 (R&D Systems) and MPP-13 (in-house kit) protein concentrations in culture supernatants and serum samples were measured by ELISA, according to the manufacturer’s protocol. Signal development was performed using horseradish peroxidase/streptavidin and o-phenylenediamine dihydrochloride substrate (Sigma-Aldrich) at room temperature. Fluorescence was measured with a plate reader (Tecan, Sunrise). Samples were run in duplicate and serial dilution was performed to fall within the detection limits of the assay (0–100 ng/ml).

Real-time fluorescence-based MMP-1 activity matrix assay

The functional effect of increased expression and secretion of TIMPs in monocytes on MMP activity was studied by a real-time fluorescence based MMP activity assay. Human pro-MMP-1 (Calbiotech) was activated by 4-aminophenylmercuric acetate (0.675 mM) (Sigma) in 0.1 M Tris, pH 7.5, 0.1 M NaCl, 10 mM CaCl2, 0.05% Brij-35, 0.1% polyethylene glycol 6000 for 4 h at 37°C. Subsequently, MMP-1 was added to the phenol-red and serum-free DMEM culture supernatants from monocytes stimulated with SSc or HC serum, TLR8 or media only. The mixture of culture supernatant and activated human MMP-1 was then added to separate wells containing fluorescent FS-6 substrate (500 µM, Calbiochem). The effect of supernatant on the breakdown rate of FS-6 by the activated MMP-1 was visualised using a Perkin Elmer LS50b plate reader. For each sample, the rate of breakdown was compared with the standard containing MPP-1 (6 µg/ml), FS-6 (50 µM) and phenol red-free DMEM (Gibco).

Statistical analysis

All data are presented as mean±SEM and differences between the groups were tested for their statistical significance by non-parametric two tailed t test. A p value <0.05 was considered statistically significant; p values are expressed as follows: NS, significant; *0.05>p>0.01; **0.01>p>0.001; ***p<0.001.

RESULTS

TIMP-1 is increased in serum samples and overexpressed in circulating monocytes from patients with SSc

TIMP-1 concentrations in serum of patients with SSc were raised compared with healthy individuals (945±72 ng/ml vs 627±70 ng/ml, p=0.005) (figure 1A), in keeping with a previously published study.24 TIMP-1 concentrations did not correlate with...
skin thickening, disease onset, lung involvement, treatment status or autoantibody status (not shown). MMP-1 was below the detection limit of the assay. Furthermore, TIMP-1 gene expression in CD14 monocytes from patients with SSc and HC was analysed by qRT-PCR (figure 1B). Seven patients had diffuse cutaneous SSc, all positive for Scl-70 autoantibodies. The other patients had limited cutaneous disease and were positive for either anticentromere antibodies or antinuclear antibodies. The expression of TIMP-1 in SSc monocytes was significantly higher than in HC monocytes (p=0.021). We also measured TIMP-2 and MMP-13 in serum samples, but we found no differences in serum concentrations (see online supplementary figure S1A,B).

CD14 monocytes expressed TIMP-1 in the SSc skin
To confirm that infiltrating CD14 monocytes contribute to skin fibrogenesis by TIMP-1 production, immunohistochemical staining of SSc skin was performed. It can be seen (figure 1C) that a paraffin-embedded skin section from a patient with early diffuse SSc expressed TIMP-1 by CD14 monocytes as indicated by overlaying images from confocal microscopy owing to colocalisation.

Serum samples from patients with SSc induce de novo MyD88-dependent TIMP-1 production in HC monocytes
Next, we investigated whether soluble factors present in SSc serum might contribute to the increased TIMP-1 or MMP-1 expression in circulating monocytes. To this end HC monocytes were cultured for 4 h with 10% serum samples from HC, patients with SSc or patients with RA. As seen in figure 2A, 4 h after stimulation, gene expression of TIMP-1 in HC monocytes cultured in the presence of SSc serum (fold increase 2±0.2) was significantly raised compared with expression in HC (p=0.01) or RA (p=0.03) serum. Of note, TIMP-1 expression in monocytes was the highest after incubation with SSc serum samples containing Scl-70 autoantibodies, although this did not reach statistical significance. Interestingly, MMP-1 gene expression levels (figure 2B) after stimulation by either HC or SSc serum samples did not differ between the groups (p=0.59). Similarly to the gene expression results, TIMP-1 protein level (figure 2C) was also significantly higher in monocytes cultured in SSc serum samples (17±2 ng/ml), serum samples from HC (9±0.7 ng/ml, p=0.008) or from patients with RA (7±0.8, p=0.003) and was highest in cultures with anti-Scl-70-positive serum samples (24±7.7 ng/ml) (not shown).

To confirm that TIMP-1 was produced de novo and not carried over via serum, HC monocytes were washed twice with cold phosphate-buffered saline, and TIMP-1 production was measured as previously (figure 2D). The level of TIMP-1 directly after stimulation with serum samples was similar to that of untreated cells in both monocytes stimulated with HC (1.9±0.5 ng/ml) and SSc serum samples (1.9±0.3 ng/ml), confirming the lack of remaining TIMP-1 after incubation of serum samples. Interestingly, 24 h later (figure 2D), the level of TIMP-1 increased in monocytes stimulated with SSc serum samples (19±2.2 ng/ml) compared with HC serum samples (8±1.2 ng/ml), but pretreatment with 50 μM MyD88 inhibitory peptide
significantly attenuated de novo SSc sera-driven TIMP-1 secretion (7.7±1.4 ng/ml, p=0.0002). In contrast, preincubation with 50 μM scramble peptide (figure 3A,B) did not affect TIMP-1 production, indicating TLR-dependent induction of TIMP-1 synthesis by SSc serum samples. Interestingly, the level of TIMP-1 slightly increased upon stimulation with HC serum samples (fold increase=2.8) compared with untreated cells, suggesting that other factors such as IL-10 or tumour necrosis factor α may also influence TIMP-1 production, but less effectively than SSc sera factors (fold increase=6.6).25 26

Furthermore, incubation of HC monocytes with 4 μg/ml of human IgG for 1 h (in order to block Fcγ receptors (FcyR)) attenuated (fold decrease=1.8) TIMP-1 production upon sera activation (figure 2E). When SSc serum samples were treated with benzonase (to degrade DNA and RNA) before stimulation, TIMP-1 production was strongly inhibited (fold decrease=1.8). In contrast, IgG block or benzonase treatment of serum samples were incubated with RNA/DNA endonuclease (benzonase) before sera stimulation; or IRAK4−/− monocytes were treated with HC and SSc serum samples and TIMP-1 secretion was measured. Statistical analysis showed that monocytes treated with SSc sera were comparable with monocytes of IgG blocked sera or monocytes stimulated with SSc sera treated with benzonase and *p<0.05, **p<0.01, ***p<0.001. Data shown in A–E represent separate experiments. IRAK, IL-1R-associated kinase.

**MMP activity is significantly reduced upon addition of supernatants from monocytes cultured in the presence of SSc serum**

To investigate whether the TIMP-1 secreted by monocytes is functionally active and impairs substrate breakdown by MMP we employed a functional matrix breakdown assay. FS-6 breakdown by MMP-1 was significantly (p=0.02) lower in the presence of supernatant from SSc serum-stimulated monocytes compared with unstimulated monocytes (figure 4). A robust reduction (59±2%) in MMP-1 activity was seen when supernatant from SSc serum-stimulated monocytes was added to active MMP-1.

**SSc monocytes respond more vigorously to TLR agonists than HC monocytes as measured by TIMP-1 secretion**

To determine which TLR agonist drives TIMP-1 production, both HC and SSc monocytes were stimulated with a panel of TLR 1–9 agonists (figure 5A). Freshly isolated CD14 monocytes from HC and patients with SSc were treated with different TLRs or media alone for 24 h, and the expression level of TIMP-1 was measured by ELISA. TLR4, TLR8 and TLR9 agonists, in particular, induced significantly strong TIMP-1 production in SSc monocytes compared with HC (TLR4 fold

---

**Figure 2** The effect of serum samples on the tissue inhibitor of metalloproteinase-1 (TIMP-1) and matrix metalloproteinase-1 (MMP-1) induction. (A) Healthy control (HC) monocytes were treated for 4 h with serum samples from HC (n=11), patients with rheumatoid arthritis (RA) (n=11) or patients with systemic sclerosis (SSc) defined by autoantibody positivity—anticentromere antibodies (n=6), Scl-70 (n=7), antinuclear antibodies (n=9)—and TIMP-1 gene expression was measured. (B) MMP-1 gene expression in HC monocytes cultured in SSc or HC serum was also analysed. Expression levels of TIMP-1 and MMP-1 were normalised to the 18S housekeeping gene and each dot represents the mean. (C) HC monocytes were stimulated with HC, rheumatoid arthritis (RA) or SSc serum samples and TIMP-1 secretion was measured 24 h later. (D) HC monocytes were pretreated or not with MyD88 inhibitory peptide for 24 h and further stimulated over 4 h either with 10% HC or SSc serum samples. De novo TIMP-1 secretion by HC monocytes was measured 24 h later. Results are representative of mean±SEM of HC (n=11) or SSc (n=13) serum samples. (E) HC monocytes were pretreated with human IgG for 1 h before stimulation with HC or SSc serum samples (IgG block); HC or SSc serum samples were incubated with RNA/DNA endonuclease (benzonase) before sera stimulation; or IRAK4−/− monocytes were treated with HC and SSc serum samples and TIMP-1 secretion was measured. Statistical analysis showed that monocytes treated with SSc sera were comparable with monocytes of IgG blocked sera or monocytes stimulated with SSc sera treated with benzonase and *p<0.05, **p<0.01, ***p<0.001. Data shown in A–E represent separate experiments. IRAK, IL-1R-associated kinase.
increase=4.0, TLR9 fold increase=3.8, TLR8 fold increase=3.4). Pretreatment with MyD88 inhibitor reduced TIMP-1 production in TLR8-stimulated monocytes, but not when incubated with control peptide (figure 5C), confirming that TIMP-1 expression is MyD88-dependent after TLR activation. Peptide treatment did not affect cell viability as determined by MTS testing (data not shown). To extend our study, monocytes isolated from an IRAK4-deficient patient (deficiency confirmed by western blotting of fibroblasts; online supplementary figure S2) also did not secrete TIMP-1 after TLRs stimulation (figure 5A). In addition, TIMP-1 gene expression in monocytes from this patient was also lower compared with HC and SSc monocytes upon TLR8 agonist stimulation (figure 5B), confirming a role for TLR signalling in TIMP-1 production. Interestingly, TLR treatment did not induce TIMP-2 and only small quantities of MMP-13 after stimulation of TLR4, 8 and 9 (see online supplementary figure S1C,D).

**Supernatant from TLR8-stimulated SSc monocytes inhibits catalytic activity of MMP-1**

To confirm that TLR8 stimulation of monocytes inhibits matrix degradation we employed a functional matrix breakdown assay. Freshly isolated HC and SSc monocytes were cultured in phenol-free DMEM media and after 24 h stimulation with TLR8 agonist, supernatant was collected and added to preactivated MMP-1. The percentage inhibition of FS-6 breakdown by supernatant from TLR8-treated SSc monocytes, normalised to untreated, was stronger (figure 6B) than that of HC monocytes (figure 6A). Statistical analysis of three independent experiments showed a similar pattern of significant TLR8-mediated MMP-1 inhibition by SSc monocytes (figure 6C) (p<0.05).

**DISCUSSION**

The importance of the innate immune system and monocytes, in particular, in the pathogenesis of SSc is increasingly recognised.27–30 Traditionally, monocytes are seen as prototypic proinflammatory cells, but recent evidence has shown that their functional capabilities extend beyond that of cytokine production alone. In this study we explored the possibility that SSc monocytes may contribute to tissue fibrosis through preferential upregulation of TIMP-1 after stimulation with SSc serum samples or TLR agonists. This was based on the observation of increased TIMP-1 concentration in serum samples from patients with SSc and the recent identification of a subset of macrophages with a repair phenotype.8 24 31 Another study found that in patients with SSc with interstitial lung disease, CD14 circulating monocytes in response to TLR4 agonist (lipopolysaccharide) overexpress CD163, IL-10 and CCL-18, which are known to stimulate collagen secretion by fibroblasts.30 We found that mRNA expression of TIMP-1 is higher in freshly
isolated SSc monocytes than in HC monocytes. Also, serum from patients with SSc induces the expression and secretion of TIMP-1 but not MMP-1 in healthy monocytes. We observed TIMP-1 expression in CD14 cells in SSc skin (figure 1), raising the possibility that circulating monocytes expressing TIMP-1 migrate into skin to contribute to fibrogenesis. This is consistent with a recent gene expression study showing differential gene expression of MMP-1 and TIMP-1, with strongly increased TIMP-1 expression in SSc skin.

Our results suggest that SSc serum samples are a source of agonists involved in TIMP-1 production, thus contributing to a profibrotic state. Likewise, Sacre et al. showed that RA macrophages and synovial membrane cultures produce also a high level of tumour necrosis factor α and IL-6 after TLR8 stimulation. Our results may imply that serum samples from patients with SSc contain ICs of autoantibodies that recognise self-nucleic acid—in particular, self-RNA or RNA-associated proteins. However, we did not detect any differences in RNA concentration or circulating ICs recognising C1q protein between HC and SSc serum samples (see online supplementary figure S5). This does not exclude the possibility that other ICs exist which contain RNA-associated autoantibodies that recognise other complement proteins. Such RNA-associated ICs might act as TLR8 ligands when they bind to abundantly expressed FcγR on the surface of monocytes, leading to TIMP-1 production. Indeed, we showed that TIMP-1 induction was attenuated when FcγR was blocked by human IgG and also when SSc serum samples were treated with DNA/RNA endonuclease.

Figure 4  Functional matrix assay of monocytes stimulated with serum samples. Preactivated matrix metalloproteinases-1 (MMP-1) was added to the conditioned media of healthy controls (triangle) or systemic sclerosis (SSc) (circle) sera-treated or unstimulated monocytes (square) and fluorescent FS-6 breakdown product was measured over the time (min). Data show represent the mean from duplicate values of one of three independent experiments (*p<0.05 for comparison of the values of MMP-1 media only with MMP-1 SSc sera medium).

Figure 5  The effect of Toll-like receptor (TLR) agonists on tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression and protein secretion in monocytes. (A) Monocytes from healthy controls (HC) (n=10) (white bars) or patients with SSc (n=10) (black bars) and monocytes isolated from the mut-IRAK4 patient (grey bars) were incubated in the presence of different TLR agonists or media alone for 24 h, and TIMP-1 secretion was determined. Statistical analysis showed that HC monocytes compared with SSc monocytes after individual TLR stimulation. (B) Relative TIMP-1 gene expression was determined and normalised to 18S housekeeping gene of total RNA isolated from HC (n=3) or SSc (n=4) or mut-IRAK4 (grey bars) monocytes after 24 h stimulation with TLR8 agonist. (C) The effect of MyD88 inhibitor on TLR8-mediated TIMP-1 production. HC monocytes (n=4) were pretreated for 24 h with 10, 20, 50, 100 μM MyD88 inhibitory peptide (white bars) or control peptide (grey bars) or media alone (black bars) and further stimulated with TLR8 agonist (ssRNA). Twenty-four hours later TIMP-1 production was measured. Statistical analysis showed a comparison of TLR8-stimulated monocytes compared with MyD88 inhibitor or control peptide treated monocytes, respectively. Each bar represents the mean±SEM, *p<0.05, **p<0.01, ***p<0.001. IRAK, IL-1R-associated kinase.
before stimulation. These findings strongly argue in favour of recognition of RNA by circulating ICs.

It was previously shown that opsonised apoptotic bodies carrying RNA-associated protein (R060) induce FcyR-dependent uptake. This IC uptake leads to TLR7/8 activation with subsequent release of proinflammatory and profibrotic factors by infiltrating macrophages in cardiac fibrosis, or pDCs in SSc. Furthermore, the presence of ICs recognising self-RNA is responsible for disease manifestations found in patients and animal models of other autoimmune diseases, including of SLE and Sjögren’s syndrome. Indeed, it was shown that serum samples from patients with SLE, containing autoantibodies to snRNPs that are taken up through the FcyR, efficiently stimulate pDCs via TLR7/8 to secrete type I IFNs and, therefore, initiate SLE. Also, lupus-prone mice developed SLE, as a result of TLR7-dependent (mouse TLR8 is non-functional) activation of B cells and pDCs. However, disease exacerbation was completely suppressed by the deletion of murine TLR7.

Notably, we also found that HC monocytes stimulated with patients’ serum samples produce TIMP-1 in a MyD88-dependent fashion, as MyD88-specific inhibitor significantly attenuated TIMP-1 production. The same pattern of TIMP-1 reduction was seen in TLR8-stimulated HC monocytes in the presence of MyD88 inhibitor. In contrast, when HC monocytes were incubated with control peptide, TIMP-1 production was on a similar level to that of TLR8 activation only, confirming the specificity of the agonist. Monocytes isolated from a TLR-deicient patient also did not secrete TIMP-1 after stimulation with serum samples or TLR agonists, suggesting an important role for monocytes in the production of profibrotic factors. Therefore, treatments that downregulate TIMP-1 production may disrupt fibrogenesis in SSc and open up a new target.

**Figure 6**  
Functional matrix assay of Toll-like receptor 8 (TLR8)-stimulated monocytes. (A, B) Preactivated matrix metalloproteinases-1 (MMP-1) was added to the conditioned media of untreated (black line) or TLR8-stimulated (grey line) healthy control (HC) or systemic sclerosis (SSc) monocytes and fluorescent FS-6 breakdown product was measured over time (min). (C) Statistical analysis of three independent experiments showing MMP-1 inhibition by HC and SSc monocytes pretreated with TLR8 agonist.

**References**

1. Chizzolini C, Bremillia NC, Montanari E, et al. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011;10:276–81.
2. Yoshiji H, Kuniyama S, Miyamoto T, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000;32:1246–54.
3. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circ Res 2003;92:827–39.
4. Weissner JF, Tissue metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145–54.
5. Iredale JP, Banerji RN, Arthur MJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996;24:176–84.
6. Kykuchi K, Kubo M, Hoshizaki T, et al. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Derm 2002;27:301–5.
7. Kikuchi K, Kubo M, Sato S, et al. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. *J Am Acad Derm* 1995;33:973–8.

8. Montagnana M, Volpe A, Lippi G, et al. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis. *Clin Biochem* 2007;40:637–42.

9. Singer AJ, Clark RAF. Cutaneous Wound Healing. *New Engl J Med* 1999;341:738–46.

10. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. *Arthritis Rheum* 2008;58:1465–74.

11. York MB, Napi T, Mangini AJ, et al. A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. *Arthritis Rheum* 2007;56:1010–20.

12. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. *Clin Chim Acta* 2012;413:3–14.

13. Clancy RM, Alvarez D, Komissarova E, et al. R60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. *J Immunol* 2010;184:2148–55.

14. Couillin I, Vasseur V, Charon S, et al. IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. *J Immunol* 2009;183:8195–202.

15. Singh MV, Swaminathan PD, Luczaé ED, et al. MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. *J Mol Cell Cardiol* 2012;52:1135–44.

16. Dickie LJ, Church LD, Coutard LR, et al. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. *Rheumatology* 2010;49:1466–71.

17. Rajagopal D, Faturcõ C, Morel Y, et al. Plasmacytoid dendritic cell-derived type I interferon is critical for the adjacent activity of Toll-like receptor 7 agonists. *Blood* 2010;115:1949–57.

18. Yang K, Puel A, Zhang S, et al. Human TLR-7, -8, and -9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. *Rheumatology* 2010;49:1466–71.

19. Eloranta ML, Lovgren T, Finke D, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. *Arthritis Rheum* 2008;59:2418–27.

20. Lovgren T, Eloranta ML, Kastner B, et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sphingosine-1-phosphate receptor-associated RNA. *Arthritis Rheum* 2006;54:1917–27.

21. Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. *Arthritis Rheum* 2008;58:2163–73.

22. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkarapalBa deficiency. *Clin Microbiol Rev* 2011;24:490–7.

23. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. *Science* 2008;321:891–6.

24. Young-Min SA, Beeton C, Laughton R, et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in normal controls. *Ann Rheum Dis* 2001;60:846–51.

25. Zhang Y, McClellan K, Fuji K, et al. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF and IL-1 beta through prostaglandin-dependent and -independent mechanisms. *J Immunol* 1998;161:3071–6.

26. Lacraz S, Nicod LP Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human monoclonal phagocytes. *J Clin Invest* 1995;96:2304–10.

27. Tourkina E, Bonser M, Dates J, et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. *Fibrogenesis Tissue Repair* 2011;4:15.

28. Higashikuwata N, Jinjin M, Makino T, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. *Arthritis Res Ther* 2010;12:R128.

29. Ambarus CA, Krausz S, van Eljak M, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. *J Immunol Methods* 2012;375:196–206.

30. Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. *Lab Invest* 2010;90:612–23.

31. Gorden KD, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. *J Immunol* 2005;174:1259–68.

32. Frost J, Ramsay MJ, Mia R, et al. Differential gene expression of MIP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc. *Rheumatology* 2012;51:1049–52.

33. Sacre SM, Le A, Gregory B, et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. *J Immunol* 2008;181:8002–9.

34. Alvarez D, Brassoulé F, Clancy RM, et al. A novel role of endothelin-1 in linking toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. *J Biol Chem* 2011;286:30444–54.

35. Avalos AM, Busconi L, Marshak-Rothstein A. Regulation of autoantibody B cell responses to endogenous TLR ligands. *Autoimmunity* 2010;43:76–83.

36. Santiago-Raber ML, Durand-Sauthier I, Wu T, et al. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. *J Autoimmun* 2009;33:339–48.

37. Gasse P, Mary C, Guenon I, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. *J Clin Invest* 2007;117:3798–801.

38. Roderer MP, Khosrotehrani K. Skin wound healing modulation by macrophages. *Int J Clin Exp Pathol* 2010;3:643–53.